Skip to Main Content

Immunomedics secured U.S. approval on Wednesday for a new drug to treat women with a particularly aggressive type of metastatic breast cancer.

The Food and Drug Administration disclosed the approval of the new drug, called Trodelvy, on its website. The drug’s review had been held up for more than a year due to problems at Immunomedics’ New Jersey manufacturing facility, now resolved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!